Enzymes acting at the N terminal end
Aminopeptidase A or angiotensinase A (L-a-aspartyl or L-csglutamylpeptide hydrolase, EC 3.4.11.7) acts on peptides with an N-terminal acidic amino acid such as Ang I, Ang II and the cholecystokinin octapeptide. Angiotensinase (APA) is identical to the murine /3-cell differentiation antigen, BP-1/6C3, which is expressed on immature (3-lineage cells [4] . It converts Ang I into Des Asp1 Ang I and Ang II into Des Asp1 Ang II, also referred to as Ang III. High APA activity has been found in human and rat glomeruli, essentially in podocytes [5-71, and in a single report in mesangial cells [8] . There is also a positive APA reaction in the brush border of the proximal tubule [6, 9] . Interestingly, administration to rats of antibodies against the APA antigen results in proteinuria associated with a membranous-like glomerulonephritis resembling that found in the model of Heyman nephritis [10] . Losartari and enalapril reduced this proteinuria, suggesting the role of Ang II in this model [11] .
Aminopeptidase N (APN, a-aminoacyl peptide hydrolase, EC 3.4.11.2) acts with a relatively broad substrate specificity on peptides with an N-terminal neutral amino acid. Hydrolysis of synthetic substrates (p-nitroanilides) shows the following order of specificity: alanine > leucine > lysine> arginine > valine [121. Its primary naturally occurring substrates are enkephalins, dynorphin, substance P, the thrombin receptor agonist peptide and Ang III. It converts Ang III into the hexapeptide Ang IV. APN is identical to CD 13 (gp 150), a cell surface glycoproteiri originally identified on subsets of normal and malignant human myeloid cells [13] . APN is widely distributed with a high density in the renal cortex. Early histochemical studies detected a high activity in the brush border of proximal tubules [14] . Using more sensitive immunocytochemical techniques, APN was found to he present both in glomeruli and proximal tubules on mouse renal sections [6, 9] . Mesangial and proximal tubule cells in culture also express APN [15, 16] . In the latter preparation, APN is considered as a marker of the apical side of the cells [16] . Aminopeptidase B (EC 3.4.11.6) also cleaves peptides with an N terminal arginine.
Aminopeptidase B is only present in the cytosol and thus is likely not to play any role in the degradation of the extracellular peptides. However, it has been shown that Ang IV could be produced by an endosomal pathway from Ang II that had been internalized in bovine adrenal medullary cells. Ang IV is rapidly released in the medium and can bind to specific receptors in an autocrine or paracrine manner [17] . Aminopeptidases A and N have been cloned [18, 19] . zinc metalloproteases belonging to the thermolysin-like enzyme group with significant homologies in their amino acid sequence and similarities in their physical properties (Table 1 ). Like neutral endopeptidase and ACE, they possess a large glycosylated extracellular domain that contains the catalytic sites. APA and APN expressions appear to be, at least in glomerular epithelial cells, under different regulations: mitogens, IFN-y and thrombin for APN, cyclic AMP and glucocorticoids for APA [12] . APA and APN formation. This side effect of ACE inhibitors has also to be taken into account when explaining their mechanism of action.
Chymases are a family of mast cell serine proteinases that are involved in peptide hormone processing [32] . In mammalians there are two distinct isoenzyme groups of chymases. Human chymase belongs to the a group. It plays a crucial role in the heart in the formation of Mg II from Mg I by splitting the Phe8-His9 bond (80 to 90% of the Mg 11-forming activity). In contrast, rat chymase-1 is a J3 chymase. It behaves as an angiotensinase because it splits the Tyr4-11e5 bond in angiotensins I and II with a 20-fold higher catalytic efficiency than the Phe8-His9 bond [33] . Chymases are synthesized as inactive precursors but are stored in secretory granules as active enzymes. Most of the secreted chymases in the heart have been found to be localized to the extracellular matrix. Since inhibition of prolylendopeptidase does not prevent the Finally, carboxypeptidase A, which splits the His'-Leu'° bond of Ang 1, must be included in this group of enzymes acting at the C terminal end. Its main source is the mast cells [40] and the product of the reaction is Ang I (1-9). Mast cells are present particularly in the heart where they synthesize chymase [321.
Carboxypeptidase A and chymase thus appear to contribute to the specificity of the human cardiac tissue for angiotensin formation and metabolism.
IN VIVO AND IN VITRO EFFECTS OF THE ANGIOTENSIN

ACTIVE FRAGMENTS
Fragments obtained by deletion of the N terminal end of angiotensin peptides: Angiotensin III and angiotensin IV Ang III. It is generally accepted that Ang III exerts its effects via the specific Ang II receptors, AT1 and AT2. Initial studies showed that Ang III had a lower affinity than Ang II for Ang 11-binding sites [41] , and that intravascular injected Ang III was much less potent than Ang II in eliciting biological responses. For example, the pressor effect of Ang Ill was ten times less potent than that of Ang II [42]. The reason for this difference was attributed to the differential catabolic rate of these peptides by the peripheral In other systems, Ang lit is as potent as or, even, more potent than Ang II. This is the case for the steroidogenic activity of Ang III in the adrenal cortex, which is equal to that of Ang II ( Ang IV. The assumption that Ang IV had no biological activity and was therefore of minor importance was based on two lines of evidence: (I) The two classes of Ang II receptors, AT, and AT2, display veiy poor affinities for Ang IV [61, 62]; (2) Ang IV administration does not elicit the well known Ang 11-dependent effects in contrast with Ang III [1, 63] . These facts were at first unanimously accepted, but supplementary data led to a novel view of the role of Ang IV. First, specific binding sites for '251-Ang IV have been found in different tissues [62, 64, 65] that are pharmacologically distinct from the classical AT1 and AT2 and differently distributed ( Fig. 3) . Second, the functions mediated by these receptors are not related to the AT1 and AT2 functions that had been already described [66, 67] . Third, some effects of Ang II are suppressed in the presence of APA or APN inhibitors, or both, which suggests that these effects are not due to Ang II but to its A targets is relatively high when compared to that of Aug II. The order of potency of the various angiotensin peptides as competitors for Aug IV is the following: Ang III > Ang 11(3-7) > Ang II (3-6) > Ang II > Ang 11(4-8) > Ang 11 (1) (2) (3) (4) (5) (6) (7) . The high affinity of Ang III toward Ang IV binding sites is, in fact, due in most cases to the rapid transformation of Ang III into Ang IV. The nonpeptide AT1 (losartan, EXP 3174, CV 11974) or AT2 (PD 123177, PD 123319) antagonists do not affect Ang IV binding [61, 63, 64, 681.
Guanosine triphosphate or its analogs also do not influence Ang IV binding [69, 70] , except in opossum kidney cells [71] . The divalent cations, Mg2 and Ca2, diminish the binding of [125I] Ang IV [69] whereas ethylenediaminetetraacetic acid, a calcium chelator, and dithiotreitol increase its binding affinity [72, 73] .
Studies on the relationships between structure and activity using various peptidic analogs have allowed the main criteria of selectivity of the AT4 receptors to be established [58, 691. These studies indicated the important role of the N terminal valine, and more precisely of a primary a-amine and a L-conformation in position number 1 in the binding process. Cleavage, methylation or cyclization of this amine resulted in an important reduction of affinity. An aromatic amino acid also seems to be necessary in position number 2 in order to maintain a high affinity binding to the receptors. The C terminal amino acids (positions 4, 5 and 6) are more flexible and may be replaced by other amino acids without major consequences. Sequential deletion of these C terminal amino acids results in a progressive decrease of affinity that, however, persists for the N terminal tripeptide Val-Tyr-Ile [58] . A specific antagonist of Ang IV, divalanal-Ang IV, has been designed by replacing the amide bond connecting the Val' and Tyr2 residues with a methylene bond isostere (CH2-NH) [74] . Of note, Moeller et al [75] reported that a decapeptide (Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe) isolated from sheep brain bound to the AT4 receptor with an affinity similar to that of Ang IV. This peptide is identical to the amino acid sequence 30-39 of sheep /3 globin and has previously been named LVV-hemorphin-7. It belongs to a family of globin fragments that can be obtained in vitro by enzymatic digestion. These compounds exhibit opioid actions [761, and noncompetitively inhibit ACE [77] . Their physiological role and, in particular, their possible influence on the renin angiotensin system remain to be elucidated.
The signal transduction after activation of the Ang IV binding sites is still debated with results varying from preparation to preparation. Bernier et a! [69] reported that cytosolic calcium, inositol phosphate, cAMP and arachidonic acid concentrations did not change in endothelial cells after stimulation by high concentrations of Ang IV. In contrast, Dulin et a! [71] found an increase in intracellular calcium concentration after treatment of opossum kidney cells by Ang IV. Czekalski et al [65] observed an increase in cAMP production in collecting duct principal cells, but only in the presence of forskolin, an activator of adenylate cyclase. Ang IV receptor molecular structure is unknown. The fact that, in most studies, Ang IV binding is not inhibited in the presence of guanylnucleotides suggests that Ang IV receptor does not belong to the seven transmembrane domain receptor family. The molecular weight of Ang IV receptor has been deduced from its partial purification after covalent linkage with disuccinimidyl suberate [69] . The predominant band observed in a polyacrylamide gel corresponded to an apparent molecular weight of 186 kDa. There were less marked heavier bands that could represent multimeric forms. Possible dimerization of the receptor suggests that it may metabolites [68] , AT4 receptors share common characteristics in the brain and peripheral tissues including adrenals, vascular smooth muscle, kidney, gut, prostate and endothelium [reviewed in 58]. Their apparent dissociation constant for Ang IV is in the nanomolar range and their density at the surface of their cell resemble growth factor or cytokine receptor. Such an hypothesis is also supported by studies using a photoprobe [581. Gel analysis of solubilized receptors from several sources indicated that the AT4 receptor was present in both monomeric (165 kDa) and heterodimeric forms. Angiotensin IV is present in blood at lower concentrations than Ang II [781. It is also formed locally in the brain and the peripheral tissues where it exerts pleiotropic effects. Administered in the cerebral ventricules, it activates neuronal pathways implicated in learning, memory and exploratory behavior [67].
Ang IV increases cerebral blood flow, but at higher doses compared with those of Ang II, it causes a reduction [58] . Topical application of both Ang II and Ang IV causes endotheliumdependent vasodilation in rabbit brain arterioles. Since the vascular response to Ang II, but not that to Ang IV, was completely blocked by amastatin, this effect could be attributed to Ang IV [79] . Ang IV is also vasodilatory in the renal circulation in contrast with Ang Ii [66] . However, it behaves as a vasoconstrictor in other vascular beds including the pulmonary circulation in the cat [80] and in the rat [81] as well as the hindlimb vascular bed in the rat [821. These opposite results are probably due to the fact that Ang IV may mimick some Ang TI effects due to its low affinity toward AT1 receptors. This conclusion is confirmed by the inhibitory effect of losartan on Ang TV-dependent vasoconstriction. In contrast, the vasodilatory effects of Ang IV are likely to be mediated by the AT4 receptors. The fact that intracerebroventricularly administered APN results in hypotension in spontaneously hypertensive rats suggests a physiological role for Ang IV in the control of blood pressure [83] . The effects of Ang IV have also been studied in in vitro systems. Several studies concluded that Ang IV caused cell hypertrophy and hyperplasia either alone [84] or in cooperation with other growth factors [58] . In particular, Ang IV could contribute to cardiac hypertrophy by stimulating RNA and DNA synthesis in cardiac fibroblasts [84] . In contrast, Ang IV antagonized Ang Il-induced increase in RNA and protein synthesis in chick heart cells [85] . in addition to its effect on cell growth, Ang IV has been shown to stimulate the synthesis of protooncogenes such as c-Fos [86] and of specific proteins. In this regard, the well-known stimulatory effect of Ang Ii on the inhibitor of type I -plasminogen activator (PAT-i) could be attributed to Ang IV. Indeed, the effect of Ang TI was suppressed by bestatin, and Ang IV itself stimulated dose-and time-dependent increases in the expression of PAT-i mRNA in cultured endothehal cells [68] .
Fragments obtained by deletion of the C terminal end of angiotensin peptides: Angiotensin 11(1-7) and angiotensin II ( 
3-7)
Angiotensin 11 (1-7. This Ang IT fragment was identified in the plasma and a variety of tissues of many species including humans at concentrations similar to or even higher than those of Ang TI.
For example, it is the major product of Ang I metabolism in human and dog kidneys [87, 88] and in porcine proximal tubule membranes [89] . Moreover, Ang II (1-7) plasma concentration was found to increase after treatment by an AT1 antagonist [90] or an ACE inhibitor [911. Ang 11(1-7) was initially thought to be an inactive fragment since it did not reproduce the vasoconstrictor, dipsogenic and aldosterone-secreting effects of Ang II [92] . It is now believed that Ang 11(1-7) is a biologically active peptide with properties that are distinct from those of Ang II and even often opposite to them. These biological effects are mediated by a specific non-AT1, non-AT2 receptor and are, in part, indirect since they often require the initial formation of prostaglandins and/or nitric oxide (No). The characteristics of the Ang 11(1-7) receptors have been described in several preparations [93, 94] . In a recent study, Tallant et al [94] reported that cultured bovine aortic endothelial cells contain a saturable, high-affinity Ang 11(1-7) binding site with an affinity close to 20 nM and a density of 1350 fmol/mg protein. There was also a low affinity binding site corresponding probably to an enzyme. Ang 11(1-7) binding was not inhibited by the AT1 or AT2 antagonists. In contrast, it was prevented by a nonselective Ang II antagonist, Sar', 11e8, Ang II. Interestingly, ['2I]-Ang 11(1-7) binding to cultured endothelial cells was completely inhibited by D-A1a7-Ang 11(1-7) with an IC50 value similar to the K0 value (20 nM). This peptide behaved as a specific antagonist of Ang 11(1-7) binding since it did not compete for Ang II binding to rat adrenals [95] . Ang II itself also competed for ['25I]-Ang 11(1-7) binding but with an IC0 value (130 nM) higher than the K0 value. This indicates that the Ang 11 (1-7) receptor recognizes Ang II, but at higher concentrations than Ang II (1-7). Conversely, Ang II (1-7) at high concentrations can compete with Ang TI for angiotensin receptors [96] , which explains the finding that losartan is capable of blocking some Ang TI (1-7) effects, including the release of [3H]-noradrenaline from rat atria [97] , the decrease in fluid absorption in the proximal tubule [95] , and the decrease of renal blood flow [98, 991 In agreement with these results, Mahon et al [100] showed that Ang 11 (1) (2) (3) (4) (5) (6) (7) behaved as a specific noncompetitive antagonist of Ang II at its AT1 receptor sites on rabbit aortic rings. Inhibition by AT1 antagonists of Ang 11(1-7) effects obtained at low concentrations has been also, but more rarely, reported [98] leaving still open the question of the possible heterogeneity of Ang 11(1-7) binding sites.
Ang 11(1-7) exerts effects in the kidney, the vessels and the brain ( Table 2 ). In contrast to the vasoconstrictor effects of Ang II, it acts as a vasodilator agent in many vascular beds including porcine and canine coronary arteries [101, 102] , porcine pial arterioles [100, 103] and feline mesenteric arteries [104] . The resulting inhibitory effect on the vascular resistance explains why Ang II (1-7) reduces blood pressure in spontaneously hypertensive rats [105] and dogs with a renovascular hypertension [106] . In transgenic (mRen-2) hypertensive rats, central administration of antibodies to Ang 11(1-7) produced hypertensive effects whereas antibodies to Ang II were hypotensive [107] . Furthermore, Ang II (1-7) activates antihypertensive mechanisms in response to Ang II administration by increasing the sensitivity of the baroreceptor reflex [108] . Ang 11(1-7) has little influence on the renal vasculature and is devoid of renal hemodynamic effects at doses that are effective in the case of Ang II [99] . Ang 11(1-7) also opposes the proliferative effect of Ang II since it inhibits the vascular smooth muscle cell growth [109] . In contrast to its lack of effect on renal vascular resistance, Ang 11(1-7) produces a marked increase in renal sodium and water excretion [99] . This is another indication of the opposite effects of Ang II and Ang 11 (1) (2) (3) (4) (5) (6) (7) . The heptapeptide increases urinary output and electrolyte excretion rates. Multiple targets are involved in the action of Ang 11(1-7) on the kidney. First, it decreases fluid and bicarbonate reabsorption in the proximal straight tubule at high concentrations (10 nmol/ liter) whereas it has opposite effects at lower concentrations (1
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AngI/\ kinins/ pmol/liter) [98] . Second, Ang 11(1-7) inhibits oxygen consumption in the rat proximal tubule which is associated with a decrease in Na,K-ATPase activity [99] . Third, Ang 11(1-7) possesses a potent peripheral antidiuretic activity in water-loaded rats that is abolished after treatment with an anti-Ang II (1-7) antagonist [110] . Fourth, Ang II (1-7) causes a modest but significant increase of glomerular filtration rate [1111. However, it has been shown that natriuresis and diuresis were independent of an increase in the glomerular filtration rate [112] . Both effects are also independent of renal innervation since they have been reported in denervated kidneys in vivo [99] and in in situ perfused rat kidneys [112] . Taken together, these results are in favor of an effect of Ang 11(1-7) on sodium and water transport irrespective of any hemodynamic change. This is confirmed by the 20% inhibition of Na flux in cultured renal epithelial cells [113] . The physiological role of Ang 11 (1) (2) (3) (4) (5) (6) (7) in the control of hydromineral balance is also suggested by the increase of its circulating levels in chronically salt-loaded rats [114] , in opposition to what is observed for Ang II. Ang 11(1-7) also influences the hydroelectrolytic balance via its actions on the brain including stimulation of arginine vasopressin release [115] and increase of neuronal activity [116] . These data are in agreement with the dense immunostaining for Ang 11 (1) (2) (3) (4) (5) (6) (7) found in the supraoptic and paraventricular nuclei of the hypothalamus [117] .
The complexity of the effects of Ang II (1-7) results from addition of direct effects of the peptide to other effects that are mediated by prostaglandin E2 (PGE2), prostaglandin 12 (PGI2) or nitric oxide. Jaiswal et al [118] reported that Ang II (1-7) stimulated the release of PGE2 and PG!2 in a dose-dependent manner (100 pmollliter to 1 jsmol/liter) with an EC50 of approximately 1 nmol/liter in porcine aortic endothelial cells. Similar effects were observed in other preparations including rat smooth muscle cells [119] , human astrocytomes [120] , glioma cells [121] and rabbit vasa deferens [122] . Whereas Ang 11(1-7) was considerably more potent than Ang II in stimulating prostaglandin release from cultured endothelial cells, it exhibited a similar potency in the latter three preparations. Ang 11(1-7) influences prostaglandin synthesis via stimulation of arachidonic release as shown in isolated proximal tubule epithelial cells [113] . This stimu!atory effect of Ang I! (1-7) on prostaglandin production was also observed in vivo since chronic infusion of the heptapeptide increased urinary prostaglandin excretion in hypertensive animals [105] . Because PGE2 and PGI2 are known to inhibit sodium reabsorption in the ascending limb of Henle's loop and water reabsorption in the collecting duct, it could be suggested that such effects of Ang 11(1-7) were mediated by both prostaglandins. This hypothesis has been confirmed, at least in part, by Hilchey and Bell-Quilley [111] who showed that indomethacin, a cyclooxygenase blocker, halved the fourfold increase in urine flow and sevenfold increase in sodium secretion rate obtained after Ang II (1-7) infusion in the rat. It has been also hypothesized but not demonstrated that the epoxyeicosatetraenoic acids (EET) derived from arachidonic acid via the P450-dependent monooxygenase pathway could be involved in the biological activity of Ang I! (1) (2) (3) (4) (5) (6) (7) in the proximal tubule [96] . Another intermediate factor for Ang 11(1-7) action is nitric oxide (NO). Indeed, Ang 11(1-7) stimulated the release of NO in porcine coronary endothelium [102] and elicited NO-dependent vasodilation in coronary artery rings [101] . More recently, Li et al [1231 studied the interaction beween Ang 11 (1) (2) (3) (4) (5) (6) (7) , NO and bradykinin. They showed that Ang (1-7) augmented the vasodilation induced by bradykinin in intact canine coronary artery rings and that this effect was abolished by a pretreatment with N-nitro-L-arginine, a NO synthase inhibitor. The mechanism implied is an inhibition of ACE activity in the presence of an excess of Ang II (1-7) , thus preventing the degradation of kinins and augmenting kinin levels which in turn stimulate NO production. Inhibition of ACE by Ang 11(1-7) was confirmed in vitro using purified ACE from canine lungs. This property of Ang 11(1-7) may explain in part its antihypertensive effects (Fig. 4 ).
Angiotensin II (3) (4) (5) (6) (7) . This peptide is produced in mammalian brain [38, 124] . Ang (3-7) represents the shortest Ang II fragment having psychoactive properties. Together with its substituted analog Leu-5, Ang (3-7) improves recognition but not spatial Ang II 1 Ang (17)/ / NO, eicosanoids/ memory in rats that have been given 1 nmol of either peptide intracerebroventricularly [1251. The receptors involved in this effect have not been clearly determined. Although AT4 sites are probably mostly implicated, AT1 sites cannot be excluded since losartan has been shown to prevent facilitation of object recognition both by Ang II and Ang 11(3-7) [126] .
Other angiotensin fragments
The Ang III sequence includes several fragments that have been shown to possess in vitro anti-ACE activity. Four fragments with ACE inhibiting activity, Val-Tyr (Ang 3-4), Ile-His-Pro-Phe (Ang 5-8), Tyr-Ile-His-Pro-Phe (Ang 4-8) and Ang IV were generated after incubation of Ang III with plasma from spontaneously hypertensive rats [127] . Val-Tyr and Ang III when injected intravenously in these rats produced a fall in diastolic blood pressure. The hypotensive effect of Ang III was attributed to its metabolites via inhibition of ACE activity. Ang I can also give birth to an endogenous inhibitor of ACE, Ang 1 (1-9) by splitting of its C terminal bond, His9-Le&°. The responsible enzyme is a carboxypeptidase. Ang I (1-9) is present at low concentrations in human and rat plasma as well as in rat kidney [128] , and has been found to competitively inhibit ACE [128] . Interestingly, a decapeptide isolated from sheep brain and identical to LVV-hemorphin 7, a fragment of f3 globin, competes with Ang IV for the AT4 receptor [75] and also inhibits ACE activity together with other hemorphins [77] . Therefore, both Ang active fragments and other naturally occurring fragments of different origin but with a related structure could contribute to ACE inactivation and, via this mechanism, to the overall regulation of the renin-angiotensin system.
CONCLUSIONS
The demonstration that Ang I and Ang II fragments exert biological effects has markedly modified our views on the final effectors and the regulation of the renin-angiotensin system. The following new points have to be now considered: 
